Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis. FB-401 will be applied topically for 16 weeks and progress will be assessed by assessment of the skin and patient reports.

Key facts

Study ID

NCT04504279

Run by

Forte Biosciences, Inc.

People needed

154

Starts

2020-10-13

Expected to finish

2021-08-19

Last updated by the study team

2021-09-16

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, ≥ 2 years of age
• Clinical diagnosis of atopic dermatitis as defined by Hanifin and Rajka criteria that has been present for ≥ 3 months before the screening visit
• Investigator Global Assessment (IGA) score of 2 (mild) or 3 (moderate) at Screening and Baseline/Day 1 using the validated IGA scale for atopic dermatitis
• EASI score ≥ 5 at the screening and the Baseline visit
• 5% to 30% (inclusive) body surface area of atopic dermatitis involvement at the screening and the baseline visit

You may not qualify if…

• Previous treatment within 4 weeks prior to the baseline visit with any of the following:
• Immunosuppressive or immunomodulating systemic drugs such as systemic (intravenous, oral, intra-articular or intramuscular) corticosteroids, azathioprine, methotrexate, cyclosporine
• Phototherapy or photo chemotherapy for atopic dermatitis
• Previous treatment within 1 week prior to the baseline visit with any of the following:
• Topical corticosteroids (does not include inhaled, intranasal or ophthalmic) or topical calcineurin inhibitors
• Topical phosphodiesterase type 4 (PDE4) inhibitor
• Use of emollients other than provided for the study
• Bleach baths
• Within 8 weeks or 5 half-lives (if known), whichever is longer, prior to the baseline visit with Janus kinase inhibitors or other investigational drug
• Within16 weeks or 5 half-lives, whichever is longer, prior to the baseline visit with dupilumab or other biologic agent to treat atopic dermatitis
• Within 1 year prior to the baseline visit with any live bacterial therapy
• Pregnant (or planning to become pregnant during the period of the study) or lactating females

Where it is running

• First OC Dermatology — Fountain Valley, California, United States
• Center for Dermatology Clinical Research, Inc. — Fremont, California, United States
• Multi-Specialty Research Associates, Inc. — Lake City, Florida, United States
• MedaPhase, Inc. — Newnan, Georgia, United States
• DS Research — Clarksville, Indiana, United States
• The Indiana Clinical Trials Center — Plainfield, Indiana, United States
• DS Research — Louisville, Kentucky, United States
• Lawrence J. Green MD LLC — Rockville, Maryland, United States
• Minnesota Clinical Study Center — New Brighton, Minnesota, United States
• Midwest Children's Health Research Institute — Lincoln, Nebraska, United States
• Dermatology Consulting Services, PLLC — High Point, North Carolina, United States
• Cyn3rgy Research — Gresham, Oregon, United States
• KGL Skin Study Center LLC — Newtown Square, Pennsylvania, United States
• Bellaire Dermatology Associates — Bellaire, Texas, United States
• Texas Dermatology and Laser Specialists — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.